Dr. Grey AI

CJC-1295

Peptide

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids with modifications to extend its biological half-life. Developed by ConjuChem Biotechnologies, it exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) which binds to albumin for an extended half-life of 6-8 days, and Modified GRF (1-29) without DAC with a half-life of approximately 30 minutes. Clinical trials demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels in healthy adults. Development was discontinued after Phase II trials, and it remains an investigational compound not approved by the FDA.

Quick Answer

What it is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids with modifications to extend its biological half-life. Developed by ConjuChem Biotechnologies, it exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) which binds to albumin for an extended half-life of 6-8 days, and Modified GRF (1-29) without DAC with a half-life of approximately 30 minutes.

Key findings

  • Grade B: Growth Hormone Levels (Growth Hormone Deficiency)
  • Grade B: IGF-1 Levels (Growth Hormone Deficiency)
  • Grade B: GH Pulse Amplitude (Growth Hormone Deficiency)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: CJC-1295

Quick Facts: CJC-1295

  • Best Evidence:Grade B
  • Conditions Studied:4
  • Research Outcomes:10
  • Grade B Findings:5
  • Key Effect:Growth Hormone Deficiency
A0
B5
C5
D0
4 conditions · 10 outcomes

Detailed Outcomes

|
B
Growth Hormone Levels
2-10 fold increase in plasma GH for 6+ days
large↑Improves
B
IGF-1 Levels
1.5-3 fold increase sustained for 9-11 days
large↑Worsens
B
GH Pulse Amplitude
7.5-fold increase in GH pulse amplitude
large↑Improves
C
Body Length/Growth
Normalized growth in GH-deficient models
moderate↑Improves
C
Lean Body Mass
Moderate improvement in lean mass (animal data)
moderate↑Improves
C
Fat Mass
Moderate reduction in adipose tissue
moderate↓Improves
C
Slow-Wave Sleep Duration
Enhanced deep sleep duration (GHRH analog data)
moderate↑Improves
C
Serum Protein Profile
Changes in apolipoprotein and immunoglobulin levels
moderate↑Improves

Research Citations (23)

Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
(2026)
PMID: 41138283
Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.
(2022)
PMID: 34736642
An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
(2022)
PMID: 35298973
Advances in the detection of growth hormone releasing hormone synthetic analogs.
(2021)
PMID: 34665524
Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.
(2020)
PMID: 32971474
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
(2019)
PMID: 30489688
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
(2016)
PMID: 26771670
Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
(2016)
PMID: 26879649
Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.
(2015)
PMID: 26382721
Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
(2012)
PMID: 21871962

Related Peptides

MOTS-c

Peptide

2 shared conditions · 27 outcomes

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene. Discovered in 2015, it regulates metabolic homeostasis, insulin sensitivity, and has been shown to mimic some beneficial effects of exercise. MOTS-c levels naturally decline with age, and the peptide is being studied for age-related metabolic diseases.

Epitalon

Peptide

2 shared conditions · 20 outcomes

Epitalon (Epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. Developed from over 35 years of Russian research on pineal gland extracts, it may support cellular longevity and regulate melatonin production. Note: Epitalon is a research peptide not approved by the FDA for human use and is not available as a regulated pharmaceutical in most countries.